ADIPOQ and breast cancer: Nevertheless, in a clinical trial including 83 patients with stage I-III breast cancer conducted by He et al., the adiponectin level of the participants was measured in 2008 and a follow-up was performed among the surviving patients after 10 years [66], and the results showed that adiponectin levels may be used as a predictor for the survival rates and to determine the patients that require more aggressive treatment.